Journal of Pharmacogenomics & Pharmacoproteomics

e-patient′s perspective path to survival monitoring own biomarkers during clinical trials using real world evidence and risk based monitoring

7^th International Conference on Predictive, Preventive and personalized Medicine & Molecular Diagnostics

October 05-06, 2017 Chicago, USA

Jack Whelan

Jack Whelan Inc., USA

Keynote: J Pharmacogenomics Pharmacoproteomics

Abstract:

Jack Whelan, an eight-year survivor of a rare, incurable blood cancer, recently diagnosed with an aggressive metastatic prostate cancer has moved from a career as IT Research Analyst to Research Advocate. Travel with Jack on an intensely personal and humorous bumpy ride on the road to Personalized Medicine is still under construction, while he is treated for his cancers. Hear his compelling, hopeful and helpful e-patient observations about how to improve health care using some latest generation information technology. Come away with some unique insight that will change your assumptions about research and health IT; get new actionable ideas about how to begin to harness real world data to improve outcomes for patients, as we seek safer more effective therapeutics using advanced analytics. A tireless Advocate, he�??s an active member with American Association for Cancer Research, received AACR�??s 2017 Distinguished Public Service Award, American Society of Clinical Oncology, the NCI�??s National Clinical Trials Network, Rare Disease Legislative Advocacy and other professional research and legislative advocacy groups. Jack hopes all of us appreciate the value and noble work of life sciences employees and companies involved in cancer research and care. A decided friend to BioPharma as an engaged, informed e-patient Opinion Leader (POL) and advocate, he regularly speaks to and for these companies, to open much-needed, lines of communications with patients, providers and policymakers. Jack understands the realities of his rare blood and metastatic prostate cancers as he has repeatedly relapsed and has been refractory to many of the therapies received thus far; however his goal is repeated periods of progression free survival during which the promise of science and delivery of successful therapeutics will be achieved. His website is located at Jack-Whelan.com.

Biography :

Jack Whelan is a retired Insitutional Invesement Research Analyst. Previously, he was a career Sales VP in Information Technology who applied his skills in IT, Research and Clinical Trials to build a venture-stage firm recently acquired by ERT Inc., the largest supplier of Clinical Trials Management Software (CTMS) and electronic Patient Reported Outcomes/Clinical Outcomes Assessment (ePRO/COA). He is a popular, gripping, enagaging and fun speaker at leading Life Sciences Conferences around the US and Europe.